Key Employer
Insights

Implications

About
Migraine

Migraine is more than a headache.4,5

Employer
Implications

The annual economic burden of migraine in the United States was estimated to be $37.1 billion. Employers feel the weight of this economic burden, incurring substantial direct and indirect costs when their employees have migraine.8,9

The annual burden of migraine in the United States
was estimated to be $37.1 billion8-10

*Based on a retrospective analysis of 220,140 migraine and 1,099,605 control claims from January 2004 through December 2004 in the Thomson Medstat Commercial Claims and Encounters database. Direct costs included diagnostic testing, emergency department utilization, and acute migraine pharmacotherapy. Dollar estimates adjusted to 2019 using the medical care component of the Consumer Price Index from the Bureau of Labor Statistics.

Based on a retrospective analysis of 6,516 migraine and 6,516 matched control claims from January 2002 through December 2003 in the Thomson Medstat Health and Productivity Management database. Drivers of indirect costs include work days lost due to workplace absence (excluding presenteeism), short-term disability, and workers’ compensation. Dollar estimates adjusted to 2019 using the medical care component of the Consumer Price Index from the Bureau of Labor Statistics.

Patients with migraine had significantly higher direct costs, overall ($11,010 vs $4,436) and in each cost category (inpatient, emergency department, outpatient, pharmacy).

Unadjusted direct all-cause healthcare costs3 Migraine (N = 71,742) No migraine (N = 71,742) Incremental difference
Mean (SD) Mean (SD)
Total annual healthcare costs $11,010 ($19,663) $4,436 ($13,801) $6,575
Inpatient $2,077 ($12,151) $742 ($7,809) $1,334
ED $605 ($1,758) $170 ($735) $436
Total outpatient $5,636 ($10,367) $2,565 ($8,673) $3,075
Outpatient pharmacy $2,692 ($5,881) $962 ($4,702) $1,730

Based on a 2008–2013 retrospective, observational cohort study using Truven Health MarketScan® Commercial and Health and Productivity Management (HPM) databases from an employer perspective. Annual unadjusted direct all-cause healthcare costs in patients with short-term disability eligibility.

MarketScan® is a registered service mark of Truven Health Analytics. Inc.

The incremental indirect cost of a migraine patient is $2,350 annually
compared with someone without migraine3,§

§The total cost did not include presenteeism as part of the estimate. Calculations based on a retrospective, observational study of claims from the Truven Health MarketScan® Commercial and Health and Productivity Management databases from January 1, 2007, to June 30, 2013, which included commercial claims and details on workplace absenteeism, short-term disability, and long-term disability for employees in the commercial database.

LT=long term; ST=short term; WA=workplace absence.

Take
Action

To support your employees’ health and improve productivity, consider taking the following steps:

Resources

Please share this information with relevant stakeholders (eg, your HR/benefits team, your internal well-being team or well-being vendor, or other Employers).



Employer Migraine Cost Estimator


Specifically designed to help estimate the economic impact of migraine in your organization using company-specific inputs.


To request access, please send an email to migrainecostestimator@amgen.com. You will receive a confirmation email within 3 business days.





An Employee Well-being Program focused on migraine awareness, education, and management.


To request access, please send an email to workingwithmigraine@amgen.com. You will receive a confirmation email within 3 business days.





resources

Migraine Issues Brief

Provides an overview on some key facts about migraine,
why employers should care, and what employers can do

resources

Working With Migraine™ Brochure

Provides a detailed overview of the employee
well-being program (including program contents)

ED=emergency department; WA=workplace absence; ST=standard term; LT=long term; AAN-AHS=American Academy of Neurology and American Headache Society.

References: 1. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventative therapy. Neurology. 2007;68:343-349. 2. Burstein R, Noseda R, Borsook D. Migraine: Multiple Processes, Complex Pathophysiology. J Nuerosci. 2015;35:6619-6629. 3. Bonafede M, Sapra S, Shah N, et al. Direct and indirect healthcare resource utilization costs among migraine patients in the United States. Headache. 2018;58:700-714. 4. Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:544-552. 5. Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of Migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553-622. 6. Headache Classification Committee of the International Headache Society (IHS). Cephalalgia. 2018;38:1-211. 7. D’Amico D, et al. Neuropsychiatr Dis Treat. 2008;4:1155-1167. 8. Hawkins K, Wang S, Rupnow M. Direct cost burden among insured US employees with migraine. Headache. 2018;58:700-714. 9. Hawkins K, Wang S, Rupnow MF. Indirect cost burden of migraine in the United States. J Occup Environ Med. 2007;49:368-374. 10. Bureau of Labor Statistics. https://data.bls.gov/timeseries/CUUR0000SAM?output_view=pct_12mths. Accessed May 13, 2020.